AngioDynamics grants equity awards to SVP Campbell

AngioDynamics Inc. reported that officer Chad Thomas Campbell, SVP/GM Vascular Access, received equity awards on July 15, 2026.

Rhea-AI Filing Summary

AngioDynamics Inc. reported that officer Chad Thomas Campbell, SVP/GM Vascular Access, received equity awards on July 15, 2026. He acquired 16,081 restricted stock units, each convertible into one share of common stock, vesting in four equal annual installments on July 15 of 2027, 2028, 2029 and 2030. He also received 16,081 performance rights, each representing a contingent right to one share, with 0–200% of the target (plus a possible 20% adjustment, for up to 240% of target) earned based on three-year total shareholder return relative to a peer group. Following these grants, he directly held 104,540 shares of common stock.

Insider Trade Summary

Grant/Award: 32,162 shares

Grant/Award 2 txns

Insider Campbell Chad Thomas

Role SVP/GM, Vascular Access

Type	Security	Shares	Price	Value
Grant/Award	Performance Right F2	16,081	$0.00	$0.00
Grant/Award	Common Stock F1	16,081	$0.00	$0.00

Holdings After Transaction: Performance Right — 16,081 contracts (Direct); Common Stock — 104,540 shares (Direct)

Footnotes (2)

1. F1. The acquisition of 16,081 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 16,081 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.
2. F2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Key Figures

Restricted stock units granted: 16,081 units Performance rights target: 16,081 rights RSU vesting schedule: 25% annually 2027–2030 +3 more

6 metrics

Restricted stock units granted 16,081 units Time-based RSUs granted to Chad Thomas Campbell on July 15, 2026

Performance rights target 16,081 rights Target number of performance rights tied to common stock

RSU vesting schedule 25% annually 2027–2030 RSUs vest in four equal annual installments starting July 15, 2027

Performance payout range 0%–240% of target 0%–200% based on TSR plus possible 20% adjustment

Campbell common shares after grant 104,540 shares Direct common stock holdings following July 15, 2026 acquisition

Performance period length 3 years Total shareholder return measured over a three-year performance period

Key Terms

restricted stock units, performance right, total shareholder return, peer group of companies

4 terms

restricted stock units financial

"represents 16,081 restricted stock units, each of which represents a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance right financial

"Each performance right represents a contingent right to receive one share"

total shareholder return financial

"earned based on total shareholder return relative to a peer group of companies"

Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.

peer group of companies financial

"return relative to a peer group of companies over a three-year performance period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did AngioDynamics (ANGO) grant to Chad Thomas Campbell?

AngioDynamics granted Chad Thomas Campbell 16,081 restricted stock units and 16,081 performance rights. Each unit or right represents a contingent claim to one share of common stock, subject to time-based vesting and performance conditions over several years.

How do the restricted stock units for AngioDynamics (ANGO) SVP Campbell vest?

The 16,081 restricted stock units vest in four equal annual installments. Exactly 25% of the RSUs vest on each of July 15, 2027, 2028, 2029, and 2030, provided the vesting conditions are satisfied at each date.

What performance conditions apply to Campbell’s AngioDynamics (ANGO) performance rights?

Each performance right is tied to total shareholder return versus a peer group over a three-year performance period. Between 0% and 200% of target can be earned, with a possible 20% adjustment, for up to 240% of target in total.

How many AngioDynamics (ANGO) common shares does Campbell hold after these awards?

After the July 15, 2026 awards, Chad Thomas Campbell directly holds 104,540 shares of AngioDynamics common stock. This figure includes the newly acquired 16,081 shares underlying the restricted stock unit grant described in the Form 4.

What happens to AngioDynamics (ANGO) performance rights that do not vest for Campbell?

Any performance rights that do not vest by the end of the three-year performance period are forfeited. The number of shares ultimately earned depends on total shareholder return performance and the potential 20% adjustment applied to calculated achievement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/22/2026 - 08:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Chad Thomas

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP/GM, Vascular Access

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		16,081(1)	A	$0	104,540	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Right	(2)	07/15/2026		A		16,081		(2)	(2)	Common Stock	16,081	$0	16,081	D

Explanation of Responses:

1. The acquisition of 16,081 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 16,081 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

2. Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)